Clinical Trial Update: Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus [Phase 3]

View source ↗

Summary

Phase 3 long-term safety data for ospemifene 60 mg daily in postmenopausal women with vulvar and vaginal atrophy have been reported, with results posted in 2013…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vulvar and Vaginal Atrophy

Drugs mentioned

• Osphena (ospemifene)

Snippet

Sponsor: Shionogi | Conditions: Atrophy, Vaginal Diseases | Phase 3 | Status: COMPLETED | Results posted: 2013-06-28